Summary
BeOne Medicines Ltd. (ONC) filed an 8-K on September 24, 2019, to announce the presentation of clinical results for its investigational anti-PD-1 antibody, tislelizumab. These important data updates were shared at the 22nd Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) in China. The company highlighted results from three ongoing clinical trials, with five oral presentations dedicated to tislelizumab, underscoring the focus and progress of this key pipeline asset.
Key Highlights
- 1Presentation of new/updated clinical results for tislelizumab from three ongoing trials at CSCO.
- 2Tislelizumab data featured in five oral presentations, indicating significant progress and investor interest.
- 3Broader data presentation at CSCO included four poster sessions covering tislelizumab, zanubrutinib, and pamiparib.
- 4The event took place from September 18-22, 2019, in Xiamen, China.
- 5This filing serves as notification of the press release detailing these clinical updates.
- 6The press release is filed as Exhibit 99.1 to the Form 8-K.
Frequently Asked Questions
The main purpose of this 8-K filing is to report that BeOne Medicines Ltd. issued a press release on September 22, 2019, announcing clinical results for its anti-PD-1 antibody, tislelizumab, presented at the 22nd Annual Meeting of the Chinese Society of Clinical Oncology (CSCO).
Tislelizumab is an investigational anti-PD-1 antibody developed by BeOne Medicines Ltd. It is a key focus for the company's oncology pipeline.
The clinical results were presented at the 22nd Annual Meeting of the Chinese Society of Clinical Oncology (CSCO), which was held in Xiamen, China, from September 18-22, 2019.
Yes, in addition to tislelizumab, BeOne Medicines also presented data on zanubrutinib and pamiparib through four poster presentations at CSCO.